References Rated PoorQuality Rating
Bao Y, Zhao T, Wang X, Qiu Y, Su M, Jia W, et al. Metabonomic variations in the drug-treated type 2 diabetes mellitus patients and healthy volunteers. J Proteome Res 2009;8(4):1623–30.P
Bergenstal R, Lewin A, Bailey T, Chang D, Gylvin T, Roberts V. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea. Curr Med Res Opin 2009;25(1):65–75.P
Berneis K, Rizzo M, Stettler C, Chappuis B, Braun M, Diem P, et al. Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with Type 2 diabetes. Expert Opin Pharmacother 2008;9(3):343–9.P
Brackenridge AL, Jackson N, Jefferson W, Stolinski M, Shojaee-Moradie F, Hovorka R, et al. Effects of rosiglitazone and pioglitazone on lipoprotein metabolism in patients with Type 2 diabetes and normal lipids. Diabet Med 2009;26(5):532–9.P
Brodows RG, Qu Y, Johns D, Kim D, Holcombe JH. Quantifying the effect of exenatide and insulin glargine on postprandial glucose excursions in patients with type 2 diabetes. Curr Med Res Opin 2008;24(5):1395–7.P
Chogtu B, Singh NP, Chawla S, Gupta U. Impact of glitazones on metabolic and haemodynamic parameters in patients with type 2 diabetes mellitus. Singapore Med J 2009;50(4):395–9.P
Erdem G, Dogru T, Tasci I, Bozoglu E, Muhsiroglu O, Tapan S, et al. The effects of pioglitazone and metformin on plasma visfatin levels in patients with treatment naive type 2 diabetes mellitus. Diabetes Res Clin Pract 2008;82(2):214–8.P
Feinglos MN, Saad MF, Pi-Sunyer FX, An B, Santiago O. Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes. Diabet Med 2005;22(8):1016–23.P
Grossman LD, Parlan G, Bailey AL, Yee G, Yu M, Chan JY. Tolerability outcomes of a multicenter, observational, open-label, drug-surveillance study in patients with type 2 diabetes mellitus treated with pioglitazone for 2 years. Clin Ther 2009;31(1):74–88.P
Horowitz M, Vilsbøll T, Zdravkovic M, Hammer M, Madsbad S. Patient-reported rating of gastrointestinal adverse effects during treatment of type 2 diabetes with the once-daily human GLP-1 analogue, liraglutide. Diabetes, obesity & metabolism 2008;10(7):593–6.P
Iliadis F, Kadoglou NP, Hatzitolios A, Karamouzis M, Alevizos M, Karamitsos D. Metabolic effects of rosiglitazone and metformin in Greek patients with recently diagnosed type 2 diabetes. In Vivo 2007;21(6):1107–14.P
Kane MP, Abu-Baker A, Busch RS. The utility of oral diabetes medications in type 2 diabetes of the young. Curr Diabetes Rev 2005;1(1):83–92.P
Monami M, Lamanna C, Marchionni N, Mannucci E. Comparison of different drugs as add-on treatments to metformin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract 2008;79(2):196–203.P
Monami M, Lamanna C, Marchionni N, Mannucci E. Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials. Diabetes Care 2008;31(7):1455–60.P
Petrica L, Petrica M, Vlad A, Dragos Jianu C, Gluhovschi G, Ianculescu C, et al. Nephro- and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial. Wien Klin Wochenschr 2009;121(23–24):765–75.P
Pfutzner A, Schondorf T, Seidel D, Winkler K, Matthaei S, Hamann A, et al. Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride. Metabolism: Clinical & Experimental 2006;55(1):20–5.P
Shaya FT, Lu ZQ, Sohn K, Weir MR. Thiazolidinediones and Cardiovascular Events In High-Risk Patients with Type-2 Diabetes Mellitus A Comparison with Other Oral Antidiabetic Agents. P and T (USA) 2009;34(Sep):490–494,499–501.P
Tolman KG, Freston JW, Kupfer S, Perez A. Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US. Drug Saf 2009;32(9):787–800.P
Tsuchiya K, Akaza I, Yoshimoto T, Hirata Y. Pioglitazone improves endothelial function with increased adiponectin and high-density lipoprotein cholesterol levels in type 2 diabetes. Endocr J 2009;56(5):691–8.P
Turkmen Kemal Y, Guvener Demirag N, Yildirir A, Atar A, Dogruk Unal A, Biyiklioglu Z. Effects of rosiglitazone on plasma brain natriuretic peptide levels and myocardial performance index in patients with type 2 diabetes mellitus. Acta Diabetol 2007;44(3):149–56.P
Vilsboll T, Brock B, Perrild H, Levin K, Lervang HH, Kolendorf K, et al. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. Diabet Med 2008;25(2):152–6.P
Vlckova V, Cornelius V, Kasliwal R, Wilton L, Shakir SA. Hypoglycaemia with Oral Antidiabetic Drugs Results from Prescription-Event Monitoring Cohorts of Rosiglitazone, Pioglitazone, Nateglinide and Repaglinide. Drug Safety (New Zealand) 2009;32(May):409–418.P
White J. Efficacy and safety of incretin based therapies: clinical trial data. J Am Pharm Assoc (2003). Sep–Oct 2009;49 Suppl 1:S30–40.P

From: Appendix D, Excluded studies and studies of poor quality

Cover of Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations
Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations: Final Original Report [Internet].
Jonas D, Van Scoyoc E, Gerrald K, et al.
Portland (OR): Oregon Health & Science University; 2011 Feb.
Copyright © 2011, Oregon Health & Science University.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.